AMGN logo

Amgen Inc.

AMGN
Healthcare|Drug Manufacturers - General|US
$460.42
+0.14 (+0.03%)
DCF Value
$902.10
Graham Number
$101.79
Cash / Share
$24.38

Financials

Financial Snapshot

Market Cap
$248.92B
Enterprise Value
$289.73B
Revenue (TTM)
$38.93B
Net Income (TTM)
$9.39B
Cash & Investments
$13.19B
Net Cash
-$40.82B
Free Cash Flow (TTM)
$9.58B
Operating CF (TTM)
$12.04B
Debt/Equity
3.76

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$38.09B$41.68B$29.30B$8.91B$10.65B$8.04B$9.30B$10.94B$11.97B$9.13B$13.19B
Operating Cash Flow
$10.35B$11.18B$11.30B$9.15B$10.50B$9.26B$9.72B$8.47B$11.49B$9.96B$12.04B
Free Cash Flow
$9.52B$10.51B$10.56B$8.53B$9.89B$8.38B$8.79B$7.36B$10.39B$8.10B$9.58B
Capital Expenditure
-$837.0M-$664.0M-$738.0M-$618.0M-$608.0M-$880.0M-$936.0M-$1.11B-$1.10B-$1.86B-$2.45B
Financing Cash Flow
-$2.60B-$6.59B-$22.49B-$15.77B-$4.87B-$8.27B-$4.04B$21.05B-$9.41B-$10.86B-$5.66B

R&D Spending

R&D (TTM)
$7.85B
R&D Intensity
20.2%
R&D Growth vs Prior
+12.5%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$22.99B$22.85B$23.75B$23.36B$25.42B$25.98B$26.32B$28.19B$33.42B$36.74B$38.93B
R&D Expense
$3.84B$3.56B$3.74B$4.12B$4.21B$6.32B$4.43B$4.78B$5.96B$6.97B$7.85B
R&D % of Revenue
16.7%15.6%15.7%17.6%16.5%24.3%16.8%17.0%17.8%19.0%20.2%
SG&A
$5.06B$4.87B$5.33B$5.15B$5.73B$5.37B$5.41B$6.18B$7.10B$7.05B$6.96B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$22.99B$22.85B$23.75B$23.36B$25.42B$25.98B$26.32B$28.19B$33.42B$36.74B$38.93B
Cost of Revenue
$4.16B$4.07B$4.10B$4.36B$6.16B$6.45B$6.41B$8.41B$12.86B$10.73B$10.13B
Gross Profit
$18.83B$18.78B$19.65B$19.01B$19.27B$19.52B$19.92B$19.77B$20.57B$26.01B$28.80B
R&D
$3.84B$3.56B$3.74B$4.12B$4.21B$6.32B$4.43B$4.78B$5.96B$6.97B$7.85B
SG&A
$5.06B$4.87B$5.33B$5.15B$5.73B$5.37B$5.41B$6.18B$7.10B$7.05B$6.96B
Operating Income
$9.79B$9.97B$10.26B$9.67B$9.14B$7.64B$9.57B$7.90B$7.26B$10.68B$13.83B
Interest Expense
$1.26B$1.30B$1.39B$1.29B$1.26B$1.20B$1.41B$2.88B$3.15B$2.75B$2.64B
Pretax Income
$9.16B$9.60B$9.54B$9.14B$8.13B$6.70B$7.35B$7.86B$4.61B$8.98B$11.05B
Net Income
$7.72B$1.98B$8.39B$7.84B$7.26B$5.89B$6.55B$6.72B$4.09B$7.71B$9.39B
EPS (Diluted)
10.242.6912.6212.8812.3110.2812.1112.497.5614.2317.24
EBITDA
$12.53B$12.86B$12.88B$12.63B$13.00B$11.30B$12.17B$14.80B$13.36B$16.90B$18.17B
Shares Out. (M)
754.00735.00665.00609.00590.00573.00541.00538.00541.00542.00546.00

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$3.24B$3.80B$6.95B$6.04B$6.27B$7.99B$7.63B$10.94B$11.97B$9.13B$13.19B
Short-Term Investments
$34.84B$37.88B$22.36B$2.87B$4.38B$48.0M$1.68B$0.00$0.00$0.00$0.00
Total Current Assets
$46.01B$49.48B$37.62B$18.44B$21.14B$19.39B$22.19B$30.33B$29.03B$29.06B$34.36B
Total Assets
$77.63B$79.95B$66.42B$59.71B$62.95B$61.16B$65.12B$97.15B$91.84B$90.59B$96.05B
Total Current Liabilities
$11.20B$9.02B$13.49B$12.84B$11.65B$12.18B$15.69B$18.39B$23.10B$25.49B$23.23B
Long-Term Debt
$30.19B$34.19B$29.51B$26.95B$32.90B$33.22B$37.35B$63.17B$56.55B$50.01B$51.61B
Total Liabilities
$47.75B$54.71B$53.92B$50.03B$53.54B$54.47B$61.46B$90.92B$85.96B$81.93B$81.70B
Stockholders' Equity
$29.88B$25.24B$12.50B$9.67B$9.41B$6.70B$3.66B$6.23B$5.88B$8.66B$14.35B
Retained Earnings
-$438.0M-$5.07B-$17.98B-$21.33B-$21.41B-$24.60B-$28.62B-$26.55B-$27.59B-$25.11B-$19.81B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$10.35B$11.18B$11.30B$9.15B$10.50B$9.26B$9.72B$8.47B$11.49B$9.96B$12.04B
Capital Expenditure
-$837.0M-$664.0M-$738.0M-$618.0M-$608.0M-$880.0M-$936.0M-$1.11B-$1.10B-$1.86B-$2.45B
Free Cash Flow
$9.52B$10.51B$10.56B$8.53B$9.89B$8.38B$8.79B$7.36B$10.39B$8.10B$9.58B
Investing Cash Flow
-$8.66B-$4.02B$14.34B$5.71B-$5.40B$733.0M-$6.04B-$26.20B-$1.05B-$1.94B-$2.63B
Financing Cash Flow
-$2.60B-$6.59B-$22.49B-$15.77B-$4.87B-$8.27B-$4.04B$21.05B-$9.41B-$10.86B-$5.66B
Issuance of Stock
$55.0M$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Repurchase of Stock
-$2.96B-$3.16B-$17.79B-$7.70B-$3.49B-$4.97B-$6.36B$0.00-$200.0M$0.00$0.00
Net Debt Issuance
$3.59B$71.0M-$1.12B-$4.51B$2.46B$795.0M$6.62B$25.68B-$4.26B-$5.68B-$152.0M
Stock Based Comp.
$311.0M$329.0M$311.0M$308.0M$330.0M$341.0M$401.0M$431.0M$530.0M$494.0M$493.0M
Net Change in Cash
-$903.0M$559.0M$3.15B-$908.0M$229.0M$1.72B-$360.0M$3.31B$1.03B-$2.84B$3.75B

Dilution Tracker

Shares Outstanding
541M
5-Year Share Growth
-8.1%
Stock Issuance (TTM)
$0.00
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
754.00735.00665.00609.00590.00573.00541.00538.00541.00542.00546.00
Change vs Prior %
—-2.5%-9.5%-8.4%-3.1%-2.9%-5.6%-0.6%0.6%0.2%0.7%
Stock Issuance
$55.0M$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Stock Repurchase
-$2.96B-$3.16B-$17.79B-$7.70B-$3.49B-$4.97B-$6.36B$0.00-$200.0M$0.00$0.00
Stock Based Comp.
$311.0M$329.0M$311.0M$308.0M$330.0M$341.0M$401.0M$431.0M$530.0M$494.0M$493.0M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
81.9%82.2%82.7%81.4%75.8%75.2%75.7%70.1%61.5%70.8%74.0%
Operating Margin %
42.6%43.6%43.2%41.4%35.9%29.4%36.3%28.0%21.7%29.1%35.5%
Net Margin %
33.6%8.7%35.3%33.6%28.6%22.7%24.9%23.8%12.2%21.0%24.1%
EBITDA Margin %
54.5%56.3%54.3%54.1%51.1%43.5%46.2%52.5%40.0%46.0%46.7%
FCF Margin %
41.4%46.0%44.5%36.5%38.9%32.3%33.4%26.1%31.1%22.0%24.6%
ROE %
25.8%7.8%67.2%81.1%77.2%88.0%179.0%107.8%69.6%89.1%85.6%
ROA %
9.9%2.5%12.6%13.1%11.5%9.6%10.1%6.9%4.5%8.5%9.8%
ROIC %
11.7%2.9%15.7%16.7%15.9%13.7%16.7%8.4%8.9%13.2%15.6%
R&D / Revenue %
16.7%15.6%15.7%17.6%16.5%24.3%16.8%17.0%17.8%19.0%20.2%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
6.1%-0.6%3.9%-1.6%8.8%2.2%1.3%7.1%18.6%9.9%
Gross Profit
8.0%-0.3%4.6%-3.3%1.4%1.3%2.0%-0.7%4.0%26.5%
Operating Income
15.6%1.8%2.9%-5.7%-5.5%-16.4%25.2%-17.4%-8.1%47.1%
Net Income
11.3%-74.4%324.2%-6.6%-7.4%-18.9%11.2%2.5%-39.1%88.5%
EPS (Diluted)
13.0%-73.7%369.1%2.1%-4.4%-16.5%17.8%3.1%-39.5%88.2%
Operating Cash Flow
14.1%7.9%1.1%-19.0%14.7%-11.8%5.0%-12.9%35.6%-13.3%
Free Cash Flow
12.9%10.5%0.4%-19.2%15.9%-15.2%4.8%-16.2%41.2%-22.1%
R&D Expense
-5.7%-7.2%4.9%10.1%2.2%50.3%-29.9%7.9%24.7%16.9%
SG&A Expense
4.5%-3.8%9.5%-3.4%11.3%-6.3%0.9%14.1%14.8%-0.6%
Total Assets
8.5%3.0%-16.9%-10.1%5.4%-2.8%6.5%49.2%-5.5%-1.4%
Book Value / Share
7.3%-13.5%-45.2%-15.5%0.4%-26.8%-42.1%71.2%-6.7%48.1%
Debt
10.1%2.2%-4.0%-11.9%10.3%1.0%16.9%65.9%-7.0%-9.1%
Diluted Shares
-1.6%-2.5%-9.5%-8.4%-3.1%-2.9%-5.6%-0.6%0.6%0.2%

Valuation

P/E (TTM)26.49
10Y Low / Med / High14.17 / 21.76 / 64.17
P/S6.39
10Y Low / Med / High4.22 / 5.37 / 6.24
P/B17.36
10Y Low / Med / High3.66 / 19.14 / 38.60
EV/EBITDA15.95
10Y Low / Med / High11.23 / 13.43 / 14.18
EV/Revenue7.44
10Y Low / Med / High5.66 / 6.55 / 7.37
P/FCF25.98
10Y Low / Med / High11.49 / 15.30 / 21.74

Intrinsic Value Models (per share)

DCF Value
$902.10
Graham Number
$101.79
Cash / Share
$24.38
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
14.1764.1715.3318.6018.5421.7621.5622.9334.2022.8426.49
P/S Ratio
4.765.565.426.245.304.945.375.474.224.796.39
P/B Ratio
3.665.0410.2915.0814.3219.1438.6024.7323.9920.3417.36
EV/EBITDA
11.2312.3412.0813.4312.4213.5914.1814.0414.1613.1115.95
EV/Revenue
6.126.946.557.266.355.916.567.375.666.037.44

Analyst Estimates & Quality

Altman Z-Score
2.55
Grey Zone
Piotroski F-Score
8
Strong

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$39.42B$41.23B$43.02B
Net Income$12.69B$13.38B$14.12B
EPS$23.49$24.97$26.73
# Analysts (EPS)162011

Dividends

Dividend/Share (TTM)
$9.94
Dividend Yield
2.16%
Frequency
Quarterly
Next Payment
Dec 11, 2026

Recent Payments

Ex-DatePay DateAmountFrequency
Nov 20, 2026Dec 11, 2026$2.52Quarterly
Aug 21, 2026Sep 11, 2026$2.52Quarterly
May 15, 2026Jun 5, 2026$2.52Quarterly
Feb 13, 2026Mar 6, 2026$2.52Quarterly
Nov 21, 2025Dec 12, 2025$2.38Quarterly
Aug 22, 2025Sep 12, 2025$2.38Quarterly
May 16, 2025Jun 6, 2025$2.38Quarterly
Feb 14, 2025Mar 7, 2025$2.38Quarterly
Nov 18, 2024Dec 9, 2024$2.25Quarterly
Aug 16, 2024Sep 6, 2024$2.25Quarterly
May 16, 2024Jun 7, 2024$2.25Quarterly
Feb 15, 2024Mar 7, 2024$2.25Quarterly
Nov 16, 2023Dec 8, 2023$2.13Quarterly
Aug 17, 2023Sep 8, 2023$2.13Quarterly
May 17, 2023Jun 8, 2023$2.13Quarterly
Feb 14, 2023Mar 8, 2023$2.13Quarterly
Nov 16, 2022Dec 8, 2022$1.94Quarterly
Aug 17, 2022Sep 8, 2022$1.94Quarterly
May 16, 2022Jun 8, 2022$1.94Quarterly
Feb 14, 2022Mar 8, 2022$1.94Quarterly

Revenue Segments

By Product

Segment202020212022202320242025
Product and Service, Other$1.18B$1.68B$1.52B$1.28B$1.40B$1.60B
Aranesp$1.57B$1.48B$1.42B$1.36B$1.34B$1.39B
ENBREL$5.00B$4.46B$4.12B$3.70B$3.32B$2.23B
Kyprolis$1.06B$1.11B$1.25B$1.40B$1.50B—
Neulasta$2.29B$1.73B$1.13B———
Otezla$2.19B$2.25B$2.29B$2.19B$2.13B$2.27B
Other Products$6.57B$5.85B$5.57B$5.26B$5.63B$7.26B
Prolia$2.76B$3.25B$3.63B$4.05B$4.37B$4.41B
Repatha (evolocumab)$887.0M$1.12B$1.30B$1.64B$2.22B—
XGEVA$1.90B$2.02B$2.01B$2.11B$2.23B$2.08B
Nplate—$1.03B$1.31B$1.48B$1.46B$1.52B
Evenity——$787.0M$1.16B——
BLINCYTO———$861.0M$1.22B$1.56B
KRYSTEXXA———$272.0M$1.19B$1.34B
TEPEZZA———$448.0M$1.85B$1.90B
Vectibix———$984.0M$1.04B$1.18B
EVENITY————$1.56B$2.10B
TEZSPIRE————$972.0M$1.48B
Repatha—————$3.02B

By Geography

Segment202020212022202320242025
Non-US$6.93B$7.79B$7.73B$8.38B$9.56B$10.33B
UNITED STATES$18.50B$18.19B$18.59B$19.81B$23.86B$26.42B